Share price · REGN
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when REGN's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 4 Nov 2026-4.4%
Nothing announced by REGN that day or the session before.
- 2 Nov 2026+3.6%
- 30 Oct 2026+13.3%
- 28 Sep 2026-4.5%
Nothing announced by REGN that day or the session before.
- 31 Jul 2026+3.3%
- 30 Jul 2026+6.2%
- 18 May 2026-9.8%
- 29 Apr 2026-6.2%
- 23 Apr 2026+2.6%
- 20 Nov 2025+4.9%
Nothing announced by REGN that day or the session before.
Share of unusual movement by asset
For each asset, the share of REGN's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(51 total)
| Target & Modality | |||
|---|---|---|---|
Aflibercept(Eylea) | Approved | VEGF-A · VEGF-A / VEGF-B / Placental Growth Factor (PlGF)Protein / enzyme therapeutic | Age-Related Macular DegenerationDiabetic Macular Edema Wet Age-Related Macular Degeneration |
Alirocumab(Praluent) | Approved | PCSK9Monoclonal antibody | Atherosclerotic Cardiovascular DiseaseHomozygous Familial Hypercholesterolemia |
| Approved | PD-1Monoclonal antibody | Non-Small Cell Lung CancerMelanoma | |
dupilumab(Dupixent) | Approved | IL-4R-alphaMonoclonal antibody | Atopic DermatitisChronic Obstructive Pulmonary DiseaseAsthmaChronic Spontaneous UrticariaPrurigo NodularisEosinophilic Esophagitis |
Evinacumab(Evkeeza) | Approved | ANGPTL3Monoclonal antibody | Homozygous Familial Hypercholesterolemia |
garetosmab(Pasatru) | Approved | Activin AMonoclonal antibody | ObesityFibrodysplasia Ossificans Progressiva |
| Approved | BCMA x CD3Multispecific antibody | Multiple Myeloma | |
| Approved | IL-6 receptorMonoclonal antibody | Rheumatoid ArthritisSystemic Juvenile Idiopathic Arthritis | |
| Phase 3 | CIDEBRNA / oligonucleotide | MASH / NASH | |
| Phase 3 | Complement C5RNA / oligonucleotide | Age-Related Macular DegenerationMyasthenia Gravis Generalized Myasthenia Gravis | |
| Phase 3 | Factor XIMonoclonal antibody | Venous Thromboembolism | |
| Phase 3 | LAG-3Monoclonal antibody | Melanoma | |
| Phase 3 | Fel d 1 (major cat allergen protein)Monoclonal antibody | AsthmaAllergic ConjunctivitisCat Allergy | |
| Phase 3 | Leptin receptorMonoclonal antibody | ObesityGeneralized Lipodystrophy | |
| Phase 3 | Transthyretin (TTR)Gene therapy / editing | Transthyretin-Mediated Amyloidosis Transthyretin Amyloidosis with Cardiomyopathy |
Discontinued programmes (1)
Development of these assets stopped. Each page states the sourced discontinuation and keeps the trials as evidence history.
Upcoming events
(86 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (1)
December 2026 (1)
What to watch
2027 (17)
January 2027 (1)
What to watch
February 2027 (2)
March 2027 (3)
May 2027 (2)
What to watch
What to watch
June 2027 (2)
July 2027 (1)
August 2027 (2)
September 2027 (1)
What to watch
October 2027 (1)
What to watch
November 2027 (2)
What to watch
What to watch
2028 (24)
January 2028 (4)
February 2028 (2)
March 2028 (2)
April 2028 (1)
What to watch
May 2028 (3)
June 2028 (3)
What to watch
What to watch
What to watch
July 2028 (1)
What to watch
August 2028 (1)
What to watch
October 2028 (3)
November 2028 (2)
What to watch
What to watch
2029 (16)
January 2029 (1)
March 2029 (2)
May 2029 (3)
June 2029 (2)
July 2029 (1)
What to watch
August 2029 (1)
What to watch
September 2029 (2)
What to watch
November 2029 (2)
What to watch
2030 (12)
January 2030 (3)
February 2030 (1)
What to watch
March 2030 (2)
May 2030 (1)
What to watch
June 2030 (1)
What to watch
July 2030 (1)
What to watch
October 2030 (2)
What to watch
What to watch
November 2030 (1)
What to watch
2031 (4)
February 2031 (1)
April 2031 (1)
What to watch
2032 (3)
March 2032 (1)
May 2032 (1)
What to watch
August 2032 (1)
What to watch
2033 (6)
January 2033 (1)
What to watch
March 2033 (1)
What to watch
April 2033 (1)
What to watch
July 2033 (1)
What to watch
September 2033 (1)
What to watch
November 2033 (1)
What to watch
2034 (1)
August 2034 (1)
What to watch
Regulatory and conference events
(34)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Coming up
Recent
The 12 most recent of 31 past events are shown.
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $5.1B | $1.8B | $3.7B+ $5.6B short-term inv. | —$1.8B operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $4.3B | $1.6B | $2.5B+ $5.5B short-term inv. | —$813M operating cash flow | report ↗ |
| 2026-Q1 | $3.6B | $1.5B | $3.0B+ $5.8B short-term inv. | —$1.1B operating cash flow | report ↗ |
| 2025-Q3 | $3.8B | $1.5B | $2.5B+ $5.9B short-term inv. | —$1.6B operating cash flow | report ↗ |
| 2025-Q2 | $3.7B | $1.4B | $2.0B+ $5.5B short-term inv. | —$1.1B operating cash flow | report ↗ |
| 2025-Q1 | $3.0B | $1.3B | $3.1B+ $5.3B short-term inv. | —$1.0B operating cash flow | report ↗ |
| 2024-Q3 | $3.7B | $1.3B | $2.0B+ $7.8B short-term inv. | —$1.3B operating cash flow | report ↗ |
| 2024-Q2 | $3.5B | $1.2B | $1.9B+ $7.9B short-term inv. | —$354M operating cash flow | report ↗ |
| 2024-Q1 | $3.1B | $1.2B | $2.6B+ $7.9B short-term inv. | —$1.5B operating cash flow | report ↗ |
| 2023-Q3 | $3.4B | $1.1B | $2.2B+ $7.8B short-term inv. | —$1.1B operating cash flow | report ↗ |
| 2023-Q2 | $3.2B | $1.1B | $1.9B+ $7.0B short-term inv. | —$1.0B operating cash flow | report ↗ |
| 2023-Q1 | $3.2B | $1.1B | $3.9B+ $5.0B short-term inv. | —$1.4B operating cash flow | report ↗ |
| 2022-Q3 | $2.9B | $911M | $3.5B+ $3.5B short-term inv. | —$629M operating cash flow | report ↗ |
| 2022-Q2 | $2.9B | $794M | $3.4B+ $4.2B short-term inv. | —$564M operating cash flow | report ↗ |
| 2022-Q1 | $3.0B | $844M | $3.4B+ $3.7B short-term inv. | —$2.1B operating cash flow | report ↗ |
| 2021-Q3 | $3.5B | $665M | $3.4B+ $2.4B short-term inv. | —$3.4B operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $14.3B | $5.9B | $3.1B+ $5.5B short-term inv. | —$5.0B operating cash flow | report ↗ |
Regeneron reported full-year 2025 revenue of $14,342.9M, up 1.0% YoY, with R&D spend of $5,850.2M, up 14.0% YoY. The company ended the period with cash and equivalents of $3,123.7M and reported net income of $4,504.9M.
The filing did not include financial guidance. Key clinical and regulatory developments included FDA approvals for EYLEA HD in retinal vein occlusion and an every-four-week dosing option, FDA and EC approvals for Lynozyfic in relapsed/refractory multiple myeloma, and FDA approval of Dupixent for bullous pemphigoid. Regeneron also disclosed complete response letters for the EYLEA HD pre-filled syringe and odronextamab in follicular lymphoma related to a manufacturing site inspection, as well as positive Phase 3 results for itepekimab in COPD, garetosmab in fibrodysplasia ossificans progressiva, cemdisiran in myasthenia gravis, and allergy immunotherapy candidates.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $14.2B | $5.1B | $2.5B+ $6.5B short-term inv. | —$4.4B operating cash flow | report ↗ |
| 2023-FY | $13.1B | $4.4B | $2.7B+ $8.1B short-term inv. | —$4.6B operating cash flow | report ↗ |
| 2022-FY | $12.2B | $3.6B | $3.1B+ $4.6B short-term inv. | —$5.0B operating cash flow | report ↗ |
| 2021-FY | $16.1B | $2.9B | $2.9B+ $2.8B short-term inv. | —$7.1B operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 166 sales ($64.6M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-17 | SING GEORGE L · director | Open-market sale | 176 | $956.96 | $168K | Form 4 |
| 2026-11-17 | MURPHY ANDREW J · Co-Chief Scientific Officer | Open-market sale | 93 | $949.69 | $88K | Form 4 |
| 2026-11-17 | SING GEORGE L · director | Open-market sale | 359 | $957.49 | $344K | Form 4 |
| 2026-11-17 | MURPHY ANDREW J · Co-Chief Scientific Officer | Open-market sale | 74 | $950.61 | $70K | Form 4 |
| 2026-11-17 | SING GEORGE L · director | Open-market sale | 465 | $958.11 | $446K | Form 4 |
| 2026-11-17 | MURPHY ANDREW J · Co-Chief Scientific Officer | Open-market sale | 298 | $951.75 | $284K | Form 4 |
| 2026-11-17 | MURPHY ANDREW J · Co-Chief Scientific Officer | Open-market sale | 220 | $952.75 | $210K | Form 4 |
| 2026-11-17 | MURPHY ANDREW J · Co-Chief Scientific Officer | Open-market sale | 671 | $953.69 | $640K | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 1,378 reporting institutions held 87.8M shares ($64.7B, 85.2% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | BlackRock, Inc. | 8,947,735 | $6.9B |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 6,654,913 | $5.1B |
| 3 | STATE STREET CORP | 4,664,478 | $3.6B |
| 4 | Dodge & Cox | 4,458,238 | $3.4B |
| 5 | JPMORGAN CHASE & CO | 4,311,806 | $3.2B |
| 6 | FRANKLIN RESOURCES INC | 2,722,071 | $2.1B |
| 7 | GEODE CAPITAL MANAGEMENT, LLC | 2,607,732 | $2.0B |
| 8 | Nuveen, LLC | 2,065,064 | $1.6B |
| 9 | LOOMIS SAYLES & CO L P | 1,912,310 | $1.5B |
| 10 | WELLINGTON MANAGEMENT GROUP LLP | 1,837,459 | $1.4B |
| 11 | Invesco Ltd. | 1,724,478 | $1.3B |
| 12 | VANGUARD PORTFOLIO MANAGEMENT LLC | 1,720,774 | $1.3B |
| 13 | FMR LLC | 1,518,192 | $1.2B |
| 14 | Capital World Investors | 1,419,000 | $1.1B |
| 15 | MORGAN STANLEY | 1,319,329 | $1.0B |